A strong EU regulatory framework on medical cannabis is needed to provide investors with stability but also to give peace of mind to patients struggling with fragmented legislation among member states, socialist MEP Miriam Dalli said.
The European Union authorised the marketing of a vaccine against Ebola on Monday (11 November), permitting the first wider commercial use of a protection that has helped stem an outbreak in DR Congo.
The European Medicines Agency is looking to sublet its former headquarters in the financial district of London, after a British court ruled on Wednesday (20 February) that it cannot break its lease despite the UK’s withdrawal from the EU.
The European Medicines Agency (EMA) said Thursday it is conducting a review of the health effects on patients of a widely used blood pressure medication recalled around the world last month.
The European Medicines Agency (EMA) is to scale back operations further as it copes with higher than expected staff losses, triggered by the watchdog's forced relocation from London to Amsterdam because of Brexit.
Health risks being forgotten in Brexit negotiations, potentially delaying the availability of new medicines and imposing large costs on manufacturers, public health leaders have warned.
The smooth transition of the EU drug agency from London to Amsterdam is threatened by delays in the Netherlands, whose bid to win the agency may have been misleading, a top representative of Italian pharmaceuticals told EURACTIV.com.
The preparations for relocating the European Medicines Agency to the Netherlands next year are underway and on schedule, a senior Dutch government official in the EU told EURACTIV.com on Wednesday (31 January), after recent media reports suggested that...
Dutch officials and the head of the European Medicines Agency (EMA) sought yesterday (29 January) to allay any jitters among the agency's 900 London-based staff who are being asked to move to Amsterdam because of Britain's departure from the EU.
Public health organisations and EU lawmakers say the closed-door meetings before the submission of a new drug between the pharma industry and the European Medicines Agency (EMA), a key player in the continent’s healthcare industry, should be more transparent.